Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 years

Jin Young Ahn(Yonsei University), Jun Yong Choi(Ajou University), Young Goo Song(Yonsei University), Sang Hwan Seo(International Vaccine Institute), Yoonjeong Choi(Korea University), Jung Won Woo(Genexine (South Korea)), You Suk Suh(Sahmyook Medical Center), Han Young Seo(Yonsei University), Jeong-Eun Kwak(Korea Advanced Institute of Science and Technology), Young Chul Sung(Genexine (South Korea)), Su‐Hyung Park(Korea Advanced Institute of Science and Technology), Jeongsoo Lee(Korea Advanced Institute of Science and Technology), Minwoo Kim(Yonsei University), Jong‐Won Oh(Yonsei University), Manki Song(International Vaccine Institute), Kyoung Hwa Lee(Yonsei University), Jin Won Youn(Genexine (South Korea)), Eui‐Cheol Shin(Korea Advanced Institute of Science and Technology)
medRxiv
June 1, 2021
Cited by 5


Related Papers